AMH (Anti-Muellerian hormone) variants and mutations
AMH (also known as Anti-Muellerian hormone) is a human protein-coding gene encoding an anti-Muellerian hormone protein. During male fetal development, it drives regression of the Mullerian ducts and therefore prevents formation of female internal reproductive structures. Loss of AMH signaling can cause persistent Mullerian duct syndrome in otherwise virilized 46,XY individuals. This analysis covers 1,383 AMH variants and mutations. Of these, 99% have computational variant effect predictions. Disease context includes persistent Mullerian duct syndrome, Persistent Müllerian duct syndrome, and genetic non-acquired premature ovarian failure. Example AMH variants include R2G, R2L, and R2P.
Variant analysis overview
- Gene: AMH
- Protein: Anti-Muellerian hormone
- UniProt accession: P03971
- Organism: Homo sapiens
- Variants analyzed: 1383
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 955 unspecified-consequence records; 50 frameshift variants; 115 synonymous variants; 240 missense variants; 14 stop-gained variants; 3 in-frame deletions; 1 splice-region variants; 5 substitution
- Prediction scores: 1,367 variants have prediction scores (99% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: persistent Mullerian duct syndrome, Persistent Müllerian duct syndrome, genetic non-acquired premature ovarian failure, hereditary disease, polycystic ovary syndrome, obesity disorder, endometriosis, cancer, Obesity, obesity due to melanocortin 4 receptor deficiency, 46,XY disorder of sex development due to isolated 17,20 lyase deficiency, systemic lupus erythematosus.
Protein structure and variant hotspots
- Protein features: 2 post-translational modification sites.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable AMH variants
Examples include R2G, R2L, R2P, R2Q, R2W, R2R, D3A, D3E. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- R2G (p.Arg2Gly), ExAC rs774060964, TOPMed rs774060964, gnomAD rs774060964, REVEL 0.22, CADD 1.12
- R2L (p.Arg2Leu), ExAC rs767665662, TOPMed rs767665662, gnomAD rs767665662, REVEL 0.23, CADD 0.00, Likely benign
- R2P (p.Arg2Pro), ExAC rs767665662, TOPMed rs767665662, gnomAD rs767665662, REVEL 0.22, CADD 0.01, Likely benign
- R2Q (p.Arg2Gln), rs767665662, ClinGen CA9062701, ClinVar RCV002596912, ClinVar RCV003167439, REVEL 0.19, CADD 0.00, Conflicting interpretations, not provided; Inborn genetic diseases
- R2W (p.Arg2Trp), ExAC rs774060964, TOPMed rs774060964, gnomAD rs774060964, REVEL 0.27, CADD 11.10
- R2R (p.Arg2Arg), gnomAD 19-2249336-C-A, CADD 0.83
- D3A (p.Asp3Ala), ExAC rs752774158, gnomAD rs752774158, REVEL 0.18, CADD 0.43
- D3E (p.Asp3Glu), TOPMed rs1295763433, gnomAD rs1295763433, REVEL 0.15, CADD 0.24
- D3Y (p.Asp3Tyr), gnomAD 19-2249339-G-T, REVEL 0.20, CADD 13.90
- D3N (p.Asp3Asn), gnomAD 19-2249339-G-A, REVEL 0.14, CADD 8.71
- D3D (p.Asp3Asp), gnomAD 19-2249341-C-T, CADD 0.24
- L4V (p.Leu4Val), gnomAD 19-2249342-C-G, REVEL 0.19, CADD 0.09
- L4M (p.Leu4Met), gnomAD 19-2249342-C-A, REVEL 0.27, CADD 0.45
- L4L (p.Leu4Leu), rs1264306428, gnomAD 19-2249342-C-T, CADD 0.40
- L4P (p.Leu4Pro), gnomAD 19-2249343-T-C, REVEL 0.15, CADD 0.74
- L4Q (p.Leu4Gln), gnomAD 19-2249343-T-A, REVEL 0.14, CADD 0.25
- P5L (p.Pro5Leu), ExAC rs764523289, TOPMed rs764523289, gnomAD rs764523289, REVEL 0.18, CADD 11.00
- P5R (p.Pro5Arg), ExAC rs764523289, TOPMed rs764523289, gnomAD rs764523289, REVEL 0.20, CADD 9.91
- P5S (p.Pro5Ser), TOPMed rs1266694938, gnomAD rs1266694938, REVEL 0.20, CADD 1.53
- P5T (p.Pro5Thr), TOPMed rs1266694938, gnomAD rs1266694938, REVEL 0.16, CADD 6.22
- P5H (p.Pro5His), gnomAD 19-2249346-C-A, REVEL 0.19, CADD 10.00
- L6F (p.Leu6Phe), TOPMed rs1184490585, gnomAD rs1184490585, REVEL 0.27, CADD 13.30
- L6V (p.Leu6Val), TOPMed rs1184490585, gnomAD rs1184490585, REVEL 0.15, CADD 9.59
- L6H (p.Leu6His), rs2024986025, gnomAD 19-2249345-CCT-C, CADD 14.60
- L6I (p.Leu6Ile), gnomAD 19-2249348-C-A, REVEL 0.24, CADD 10.60
- L6P (p.Leu6Pro), gnomAD 19-2249349-T-C, REVEL 0.37, CADD 15.90
- L6L (p.Leu6Leu), rs2024986109, gnomAD 19-2249350-C-T, CADD 1.05
- T7A (p.Thr7Ala), Ensembl rs1599135956, REVEL 0.13, CADD 0.00
- T7I (p.Thr7Ile), ESP rs149953700, ExAC rs149953700, TOPMed rs149953700, gnomAD rs149953700, REVEL 0.17, CADD 5.82
- T7N (p.Thr7Asn), ESP rs149953700, ExAC rs149953700, TOPMed rs149953700, gnomAD rs149953700, REVEL 0.16, CADD 3.46
- T7P (p.Thr7Pro), Ensembl rs1599135956, SIFT 0.25
- T7S (p.Thr7Ser), ESP rs149953700, ExAC rs149953700, TOPMed rs149953700, gnomAD rs149953700, REVEL 0.12, CADD 0.00
- T7T (p.Thr7Thr), gnomAD 19-2249353-C-T, CADD 0.37
- S8I (p.Ser8Ile), 1000Genomes rs145122767, ExAC rs145122767, TOPMed rs145122767, gnomAD rs145122767, REVEL 0.23, CADD 0.00, Uncertain significance
- S8N (p.Ser8Asn), 1000Genomes rs145122767, ExAC rs145122767, TOPMed rs145122767, gnomAD rs145122767, REVEL 0.19, CADD 0.00, Uncertain significance
- S8T (p.Ser8Thr), rs145122767, ClinGen CA9062706, ClinVar RCV003885069, 1000Genomes rs145122767, REVEL 0.20, CADD 0.00, Uncertain significance, not provided
- S8G (p.Ser8Gly), gnomAD 19-2249335-G-GCGG, CADD 23.50
- S8R (p.Ser8Arg), gnomAD 19-2249356-C-A, REVEL 0.16, CADD 0.24
- S8S (p.Ser8Ser), gnomAD 19-2249356-C-T, CADD 0.58
- L9M (p.Leu9Met), rs1179977361, ClinGen CA403237892, ClinVar RCV002912204, TOPMed rs1179977361, REVEL 0.27, CADD 18.40, Uncertain significance, Inborn genetic diseases
- L9P (p.Leu9Pro), rs1390944850, gnomAD 19-2249354-AGCCTG, CADD 18.30
- L9W (p.Leu9Trp), rs1269596532, gnomAD 19-2249355-GC-G, CADD 9.89
- L9L (p.Leu9Leu), rs1179977361, gnomAD 19-2249357-C-T, CADD 2.25
- A10S (p.Ala10Ser), gnomAD rs2024986333, REVEL 0.22, CADD 6.03
- A10V (p.Ala10Val), 1000Genomes rs200057041, TOPMed rs200057041, gnomAD rs200057041, REVEL 0.19, CADD 0.94
- A10P (p.Ala10Pro), gnomAD 19-2249360-G-C, REVEL 0.22, CADD 3.10
- A10T (p.Ala10Thr), gnomAD 19-2249360-G-A, REVEL 0.21, CADD 7.90
- A10D (p.Ala10Asp), gnomAD 19-2249361-C-A, REVEL 0.18, CADD 6.32
- A10A (p.Ala10Ala), gnomAD 19-2249362-C-T, CADD 0.38
- L11Q (p.Leu11Gln), TOPMed rs1342627903, REVEL 0.42, CADD 22.50
- L11V (p.Leu11Val), ExAC rs779229624, TOPMed rs779229624, gnomAD rs779229624, REVEL 0.24, CADD 19.20, Uncertain significance, Inborn genetic diseases
- L11* (p.Leu11Ter), gnomAD 19-2249360-GC-G, CADD 10.20
- L11L (p.Leu11Leu), rs779229624, gnomAD 19-2249363-C-T, CADD 2.64
- L11I (p.Leu11Ile), gnomAD 19-2249363-C-A, REVEL 0.25, CADD 19.70
- L11P (p.Leu11Pro), gnomAD 19-2249364-T-C, REVEL 0.54, CADD 22.70
- V12G (p.Val12Gly), rs149082963, ClinGen CA9062708, ClinVar RCV000439837, ClinVar RCV003972605, REVEL 0.60, CADD 18.20, Uncertain significance, Differences in sex development; not provided
- V12M (p.Val12Met), TOPMed rs1158145757, gnomAD rs1158145757, REVEL 0.24, CADD 9.03
- V12L (p.Val12Leu), gnomAD 19-2249366-G-T, REVEL 0.12, CADD 5.23
- V12E (p.Val12Glu), gnomAD 19-2249367-T-A, REVEL 0.36, CADD 18.90
- V12V (p.Val12Val), gnomAD 19-2249368-G-T, CADD 1.00
- L13M (p.Leu13Met), ExAC rs754607106, TOPMed rs754607106, gnomAD rs754607106, REVEL 0.28, CADD 22.00
- L13V (p.Leu13Val), ExAC rs754607106, TOPMed rs754607106, gnomAD rs754607106, REVEL 0.26, CADD 17.50
- L13L (p.Leu13Leu), rs754607106, gnomAD 19-2249369-C-T, CADD 3.49
- S14A (p.Ser14Ala), ExAC rs747624096, gnomAD rs747624096, REVEL 0.07, CADD 0.07
- S14T (p.Ser14Thr), ExAC rs747624096, gnomAD rs747624096
- S14Y (p.Ser14Tyr), NCI-TCGA TCGA novel, REVEL 0.12, CADD 0.03, Variant assessed as somatic; moderate impact.
- S14S (p.Ser14Ser), gnomAD 19-2249374-T-C, CADD 0.53
- A15S (p.Ala15Ser), TOPMed rs1011797489, gnomAD rs1011797489, REVEL 0.09, CADD 1.87
- A15V (p.Ala15Val), Ensembl rs2024986744, REVEL 0.09, CADD 1.82
- A15T (p.Ala15Thr), gnomAD 19-2249375-G-A, REVEL 0.09, CADD 1.89
- A15D (p.Ala15Asp), gnomAD 19-2249376-C-A, REVEL 0.12, CADD 8.83
- A15A (p.Ala15Ala), gnomAD 19-2249377-C-A, CADD 0.25, MutPred 0.32
- L16P (p.Leu16Pro), TOPMed rs2024986856, REVEL 0.34, CADD 17.90
- L16W (p.Leu16Trp), gnomAD 19-2249375-GC-G, CADD 12.70
- L16M (p.Leu16Met), gnomAD 19-2249378-C-A, REVEL 0.12, CADD 0.02
- L16V (p.Leu16Val), gnomAD 19-2249378-C-G, REVEL 0.11, CADD 0.05
- L16L (p.Leu16Leu), rs777482098, gnomAD 19-2249378-C-T, CADD 0.22
- G17E (p.Gly17Glu), gnomAD rs1286822524, REVEL 0.24, CADD 21.70
- G17R (p.Gly17Arg), gnomAD rs1223752366, REVEL 0.41, CADD 23.80
- G17W (p.Gly17Trp), gnomAD 19-2249381-G-T, REVEL 0.46, CADD 24.30
- G17V (p.Gly17Val), gnomAD 19-2249382-G-T, REVEL 0.45, CADD 23.40
- G17G (p.Gly17Gly), gnomAD 19-2249383-G-A, CADD 3.60, MutPred 0.19
- A18P (p.Ala18Pro), ExAC rs749214406, TOPMed rs749214406, gnomAD rs749214406, SIFT 0.16, Uncertain significance
- A18S (p.Ala18Ser), ExAC rs749214406, TOPMed rs749214406, gnomAD rs749214406, REVEL 0.17, CADD 7.60, Uncertain significance
- A18T (p.Ala18Thr), rs749214406, ClinGen CA9062714, ClinVar RCV002930470, ExAC rs749214406, REVEL 0.09, CADD 3.04, Uncertain significance, Inborn genetic diseases
- A18V (p.Ala18Val), rs61736578, ClinGen CA9062715, ClinVar RCV002182493, 1000Genomes rs61736578, REVEL 0.16, CADD 9.11, Likely benign, not provided
- A18L (p.Ala18Leu), rs1374682589, gnomAD 19-2249379-TG-T, CADD 22.70
- A18D (p.Ala18Asp), gnomAD 19-2249385-C-A, REVEL 0.20, CADD 18.70
- L19L (p.Leu19Leu), rs774158206, gnomAD 19-2249387-C-T, CADD 3.10
- L19M (p.Leu19Met), gnomAD 19-2249387-C-A, REVEL 0.22, CADD 15.00
- L19Q (p.Leu19Gln), gnomAD 19-2249388-T-A, REVEL 0.25, CADD 14.10
- L19P (p.Leu19Pro), gnomAD 19-2249388-T-C, REVEL 0.13, CADD 13.60
- L20L (p.Leu20Leu), gnomAD 19-2249390-C-T, CADD 1.05
- L20V (p.Leu20Val), gnomAD 19-2249390-C-G, REVEL 0.16, CADD 8.04
- L20M (p.Leu20Met), gnomAD 19-2249390-C-A, REVEL 0.16, CADD 8.38
- L20R (p.Leu20Arg), gnomAD 19-2249391-T-G, REVEL 0.43, CADD 18.00
- L20P (p.Leu20Pro), gnomAD 19-2249391-T-C, REVEL 0.53, CADD 22.10
- G21V (p.Gly21Val), gnomAD rs1206701792, REVEL 0.15, CADD 1.89
- G21W (p.Gly21Trp), gnomAD 19-2249393-G-T, REVEL 0.29, CADD 14.80
- G21G (p.Gly21Gly), rs1431948777, gnomAD 19-2249395-G-T, CADD 1.39
- T22A (p.Thr22Ala), ExAC rs759273427, gnomAD rs759273427, REVEL 0.23, CADD 0.03
- T22I (p.Thr22Ile), TOPMed rs1470455151, gnomAD rs1470455151, REVEL 0.28, CADD 7.41
- T22T (p.Thr22Thr), gnomAD 19-2249398-T-A, CADD 0.28
- E23K (p.Glu23Lys), NCI-TCGA TCGA novel, SIFT 0.37, Variant assessed as somatic; moderate impact.
- E23* (p.Glu23Ter), gnomAD 19-2249399-G-T, CADD 33.00
- E23V (p.Glu23Val), gnomAD 19-2249400-A-T, REVEL 0.14, CADD 5.27
- E23G (p.Glu23Gly), gnomAD 19-2249400-A-G, REVEL 0.18, CADD 4.69
- E23A (p.Glu23Ala), gnomAD 19-2249400-A-C, REVEL 0.13, CADD 2.82
- E23E (p.Glu23Glu), rs147681174, gnomAD 19-2249401-G-A, CADD 2.68
- E23D (p.Glu23Asp), gnomAD 19-2249401-G-T, REVEL 0.16, CADD 9.27
- A24P (p.Ala24Pro), ExAC rs775579158, TOPMed rs775579158, gnomAD rs775579158, REVEL 0.20, CADD 5.40
- A24T (p.Ala24Thr), ExAC rs775579158, TOPMed rs775579158, gnomAD rs775579158, REVEL 0.16, CADD 0.41
- A24S (p.Ala24Ser), gnomAD 19-2249402-G-T, REVEL 0.18, CADD 2.20
- A24V (p.Ala24Val), gnomAD 19-2249403-C-T, REVEL 0.09, CADD 5.86
- A24D (p.Ala24Asp), gnomAD 19-2249403-C-A, REVEL 0.19, CADD 11.50
- A24A (p.Ala24Ala), gnomAD 19-2249404-C-A, CADD 1.84, MutPred 0.44
- L25F (p.Leu25Phe), gnomAD 19-2249405-C-T, REVEL 0.25, CADD 5.72
- L25I (p.Leu25Ile), gnomAD 19-2249405-C-A, REVEL 0.10, CADD 2.17
- L25L (p.Leu25Leu), rs1481314667, gnomAD 19-2249407-C-T, CADD 0.11
- R26G (p.Arg26Gly), rs142456399, ClinGen CA9062720, ClinVar RCV001997140, 1000Genomes rs142456399, REVEL 0.13, CADD 1.03, Uncertain significance, not provided
- R26K (p.Arg26Lys), ExAC rs764149385, TOPMed rs764149385, gnomAD rs764149385, REVEL 0.16, CADD 0.83
- R26T (p.Arg26Thr), ExAC rs764149385, TOPMed rs764149385, gnomAD rs764149385, Uncertain significance, Inborn genetic diseases
- R26S (p.Arg26Ser), gnomAD 19-2249407-CAG-C, CADD 15.90
- R26I (p.Arg26Ile), gnomAD 19-2249409-G-T, REVEL 0.16, CADD 7.57
- R26R (p.Arg26Arg), rs1331714454, gnomAD 19-2249410-A-G, CADD 3.63
- A27T (p.Ala27Thr), TOPMed rs1199745234, REVEL 0.12, CADD 5.03
- A27S (p.Ala27Ser), gnomAD 19-2249411-G-T, REVEL 0.07, CADD 2.76
- A27V (p.Ala27Val), gnomAD 19-2249412-C-T, REVEL 0.12, CADD 5.15
- A27E (p.Ala27Glu), gnomAD 19-2249412-C-A, REVEL 0.19, CADD 0.41
- A27G (p.Ala27Gly), gnomAD 19-2249412-C-G, REVEL 0.14, CADD 2.24
- E28A (p.Glu28Ala), ExAC rs762279290, TOPMed rs762279290, gnomAD rs762279290, REVEL 0.18, CADD 13.60
- E28K (p.Glu28Lys), ExAC rs753970896, gnomAD rs753970896, REVEL 0.17, CADD 14.90
- E28* (p.Glu28Ter), gnomAD 19-2249414-G-T, CADD 33.00
- E28G (p.Glu28Gly), gnomAD 19-2249415-A-G, REVEL 0.24, CADD 15.40
- E28D (p.Glu28Asp), gnomAD 19-2249416-G-T, REVEL 0.13, CADD 0.78
- E29D (p.Glu29Asp), ExAC rs765683297, TOPMed rs765683297, gnomAD rs765683297, REVEL 0.17, CADD 5.72
- E29* (p.Glu29Ter), gnomAD 19-2249417-G-T, CADD 33.00
- E29K (p.Glu29Lys), gnomAD 19-2249417-G-A, REVEL 0.18, CADD 7.12
- P30L (p.Pro30Leu), gnomAD rs960479195, REVEL 0.20, CADD 7.78
- P30S (p.Pro30Ser), 1000Genomes rs538374149, ExAC rs538374149, TOPMed rs538374149, gnomAD rs538374149, REVEL 0.12, CADD 14.30
- P30T (p.Pro30Thr), 1000Genomes rs538374149, ExAC rs538374149, TOPMed rs538374149, gnomAD rs538374149, REVEL 0.12, CADD 13.80
- P30Q (p.Pro30Gln), gnomAD 19-2249421-C-A, REVEL 0.14, CADD 4.74
- P30P (p.Pro30Pro), gnomAD 19-2249422-A-C, CADD 0.78
- A31P (p.Ala31Pro), ExAC rs766829297, TOPMed rs766829297, gnomAD rs766829297, REVEL 0.30, CADD 18.10, Uncertain significance
- A31S (p.Ala31Ser), ExAC rs766829297, TOPMed rs766829297, gnomAD rs766829297, REVEL 0.13, CADD 6.66, Uncertain significance, Inborn genetic diseases
- A31T (p.Ala31Thr), ExAC rs766829297, TOPMed rs766829297, gnomAD rs766829297, REVEL 0.09, CADD 13.40, Uncertain significance, Inborn genetic diseases
- A31V (p.Ala31Val), gnomAD rs1224522868, REVEL 0.18, CADD 8.40
- V32L (p.Val32Leu), ExAC rs752278804, gnomAD rs752278804, REVEL 0.16, CADD 0.22
- V32M (p.Val32Met), gnomAD 19-2249426-G-A, REVEL 0.20, CADD 0.70
- V32V (p.Val32Val), gnomAD 19-2249428-G-C, CADD 0.12, MutPred 0.70
- G33C (p.Gly33Cys), NCI-TCGA TCGA novel, REVEL 0.27, CADD 13.00, Variant assessed as somatic; moderate impact.
- G33S (p.Gly33Ser), gnomAD 19-2249429-G-A, REVEL 0.10, CADD 2.51
- G33V (p.Gly33Val), gnomAD 19-2249430-G-T, REVEL 0.18, CADD 10.70
- G33G (p.Gly33Gly), gnomAD 19-2249431-C-A, CADD 3.04
- T34N (p.Thr34Asn), gnomAD rs1216590887, REVEL 0.16, CADD 4.61
- T34P (p.Thr34Pro), Ensembl rs1599136067, SIFT 0.28
- T34I (p.Thr34Ile), gnomAD 19-2249433-C-T, REVEL 0.20, CADD 7.43
- T34T (p.Thr34Thr), gnomAD 19-2249434-C-A, CADD 0.06
- S35N (p.Ser35Asn), gnomAD 19-2249436-G-A, REVEL 0.21, CADD 6.18
- S35I (p.Ser35Ile), gnomAD 19-2249436-G-T, REVEL 0.22, CADD 13.70
- S35S (p.Ser35Ser), gnomAD 19-2249437-T-C, CADD 4.44
- G36A (p.Gly36Ala), TOPMed rs746313611, gnomAD rs746313611, REVEL 0.15, CADD 3.71
- G36D (p.Gly36Asp), TOPMed rs746313611, gnomAD rs746313611, REVEL 0.40, CADD 11.50
- G36S (p.Gly36Ser), gnomAD 19-2249438-G-A, REVEL 0.20, CADD 12.90
- G36G (p.Gly36Gly), rs1273700894, gnomAD 19-2249440-C-T, CADD 0.49
- L37F (p.Leu37Phe), 1000Genomes rs201699789, ExAC rs201699789, TOPMed rs201699789, gnomAD rs201699789, REVEL 0.39, CADD 19.40
- L37I (p.Leu37Ile), gnomAD 19-2249441-C-A, REVEL 0.36, CADD 15.00
- L37P (p.Leu37Pro), gnomAD 19-2249442-T-C, REVEL 0.34, CADD 17.50
- L37L (p.Leu37Leu), rs777384484, gnomAD 19-2249443-C-T, CADD 3.08
- I38T (p.Ile38Thr), gnomAD rs1350913582, REVEL 0.32, CADD 11.10
- I38I (p.Ile38Ile), rs748840055, gnomAD 19-2249446-C-A, CADD 5.68
- F39F (p.Phe39Phe), gnomAD 19-2249449-C-T, CADD 0.37
- F39L (p.Phe39Leu), gnomAD 19-2249449-C-A, REVEL 0.28, CADD 0.14
- R40* (p.Arg40Ter), ExAC rs757212843, TOPMed rs757212843, gnomAD rs757212843, CADD 24.50, Likely pathogenic
- R40L (p.Arg40Leu), 1000Genomes rs576266262, ExAC rs576266262, TOPMed rs576266262, gnomAD rs576266262, REVEL 0.24, CADD 0.10
- R40P (p.Arg40Pro), 1000Genomes rs576266262, ExAC rs576266262, TOPMed rs576266262, gnomAD rs576266262, REVEL 0.16, CADD 0.55
- R40Q (p.Arg40Gln), 1000Genomes rs576266262, ExAC rs576266262, TOPMed rs576266262, gnomAD rs576266262, REVEL 0.14, CADD 0.26
- R40E (p.Arg40Glu), gnomAD 19-2249448-TC-T, CADD 3.08
- R40R (p.Arg40Arg), rs757212843, gnomAD 19-2249450-C-A, CADD 0.28
- E41K (p.Glu41Lys), rs1376893013, NCI-TCGA Cosmic COSV9967, gnomAD rs1376893013, REVEL 0.11, CADD 6.06, Variant assessed as somatic; moderate impact.
Public AMH analysis runs
- AMH analysis run — AMH (1,383 variants) — completed 2026-08-19